Tiziana Life Sciences Past Earnings Performance
Past criteria checks 0/6
Tiziana Life Sciences's earnings have been declining at an average annual rate of -17.4%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-17.4%
Earnings growth rate
-20.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -146.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?
Sep 19
We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate
Jun 03Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?
Jan 16Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy
Oct 12Tiziana chief medical officer further increases holdings in company
Sep 23Tiziana Life Sciences executive chairman further raises stake in company
Sep 16Tiziana executive chairman raises stake in company again, buys more shares
Aug 25Tiziana Life Sciences discloses share purchase by executive chairman
Aug 17Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?
Aug 15Tiziana Life Sciences CEO Kunwar Shailubhai resigns
Jul 15Revenue & Expenses BreakdownBeta
How Tiziana Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -20 | 10 | 9 |
| 31 Mar 23 | 0 | -17 | 6 | 11 |
| 31 Dec 22 | 0 | -15 | 2 | 13 |
| 30 Sep 22 | 0 | -13 | 1 | 14 |
| 30 Jun 22 | 0 | -11 | 0 | 15 |
| 31 Mar 22 | 0 | -17 | 7 | 14 |
| 31 Dec 21 | 0 | -23 | 14 | 13 |
| 30 Sep 21 | 0 | -31 | 23 | 12 |
| 30 Jun 21 | 0 | -38 | 31 | 11 |
| 31 Mar 21 | 0 | -32 | 28 | 8 |
| 31 Dec 20 | 0 | -26 | 24 | 6 |
| 30 Sep 20 | 0 | -18 | 16 | 4 |
| 30 Jun 20 | 0 | -10 | 7 | 3 |
| 31 Mar 20 | 0 | -10 | 7 | 3 |
| 31 Dec 19 | 0 | -9 | 6 | 4 |
| 30 Sep 19 | 0 | -8 | 6 | 4 |
| 30 Jun 19 | 0 | -8 | 5 | 5 |
| 31 Mar 19 | 0 | -8 | 5 | 5 |
| 31 Dec 18 | 0 | -8 | 4 | 6 |
| 30 Sep 18 | 0 | -8 | 4 | 6 |
| 30 Jun 18 | 0 | -9 | 5 | 6 |
| 31 Mar 18 | 0 | -9 | 5 | 6 |
| 31 Dec 17 | 0 | -9 | 4 | 6 |
| 30 Sep 17 | 0 | -11 | 5 | 6 |
| 30 Jun 17 | 0 | -12 | 6 | 6 |
| 31 Mar 17 | 0 | -10 | 5 | 5 |
| 31 Dec 16 | 0 | -9 | 5 | 4 |
| 30 Sep 16 | 0 | -9 | 4 | 5 |
| 30 Jun 16 | 0 | -9 | 3 | 6 |
| 31 Mar 16 | 0 | -11 | 4 | 8 |
| 31 Dec 15 | 0 | -13 | 3 | 9 |
| 30 Sep 15 | 0 | -11 | 4 | 7 |
| 30 Jun 15 | 0 | -9 | 4 | 5 |
| 31 Mar 15 | 0 | -7 | 3 | 3 |
Quality Earnings: TLSA is currently unprofitable.
Growing Profit Margin: TLSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TLSA is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.
Accelerating Growth: Unable to compare TLSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: TLSA has a negative Return on Equity (-146.68%), as it is currently unprofitable.